Holen Sie sich die Stockscreener-App
3.92
2.00%
-0.08
Vorhandelsmarkt:
3.92
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$4.00
Offen:
$4.03
24-Stunden-Volumen:
2.61M
Relative Volume:
0.89
Marktkapitalisierung:
$345.97M
Einnahmen:
$409.00K
Nettoeinkommen (Verlust:
$-101.35M
KGV:
-2.3902
EPS:
-1.64
Netto-Cashflow:
$-71.49M
1W Leistung:
+0.26%
1M Leistung:
+6.81%
6M Leistung:
-5.77%
1J Leistung:
-34.88%
1-Tages-Spanne:
$3.90
$4.11
1-Wochen-Bereich:
$3.85
$4.1799
52-Wochen-Spanne:
$2.90
$11.16
Altimmune Inc Stock (ALT) Company Profile
Firmenname
Altimmune Inc
Sektor
Branche
Telefon
(240) 654-1450
Adresse
910 CLOPPER ROAD, GAITHERSBURG, MD
Vergleichen Sie ALT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
3.92 | 353.03M | 409.00K | -101.35M | -71.49M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Fortgesetzt | Goldman | Sell |
| 2025-02-28 | Eingeleitet | William Blair | Mkt Perform |
| 2025-01-08 | Eingeleitet | Stifel | Buy |
| 2024-11-12 | Eingeleitet | UBS | Buy |
| 2024-04-29 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-01-24 | Eingeleitet | Goldman | Neutral |
| 2023-03-22 | Herabstufung | Goldman | Buy → Neutral |
| 2022-12-01 | Eingeleitet | Goldman | Buy |
| 2021-12-29 | Fortgesetzt | Jefferies | Buy |
| 2021-06-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-02-11 | Eingeleitet | Guggenheim | Buy |
| 2020-12-14 | Eingeleitet | Jefferies | Buy |
| 2020-11-12 | Bestätigt | B. Riley Securities | Buy |
| 2020-09-25 | Eingeleitet | B. Riley FBR | Buy |
| 2020-08-14 | Eingeleitet | Evercore ISI | Outperform |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-07-28 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-02-24 | Fortgesetzt | ROTH Capital | Buy |
| 2019-07-19 | Eingeleitet | ROTH Capital | Buy |
| 2017-10-09 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Altimmune Inc Aktie (ALT) Neueste Nachrichten
Altimmune (NASDAQ:ALT) Receives Buy Rating from HC Wainwright - MarketBeat
ALT Stock: HC Wainwright & Co. Reiterates 'Buy' Rating with $12 - GuruFocus
Altimmune, Inc. (NASDAQ:ALT) Receives Average Rating of “Hold” from Analysts - Defense World
Altimmune, Inc. (NASDAQ:ALT) Receives Average Rating of "Hold" from Analysts - MarketBeat
ALTIMMUNE ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Pleasing Signs As A Number Of Insiders Buy Altimmune Stock - Yahoo Finance
PFG Investments LLC Has $46,000 Stock Position in Altimmune, Inc. $ALT - Defense World
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Altimmune, Inc.(ALT) Shareholders - Sahm
Investors who lost money on Altimmune, Inc. (ALT) should contact Levi & Korsinsky about pending Class ActionALT - GlobeNewswire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune - Business Wire
October 6, 2025 Deadline Approaching: Join Class Action Against Altimmune, Inc. (ALT)Contact Levi & Korsinsky - ACCESS Newswire
ALTIMMUNE FINAL DEADLINE REMINDER: Bragar Eagel & Squire, - GlobeNewswire
Investors in Altimmune, Inc. Should Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your RightsALT - PR Newswire
ALT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune - FinancialContent
ALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
ALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Altimmune, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
Faruqi & Faruqi Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 6, 2025ALT - Newsfile
Join Class Action to Recover Losses from Altimmune, Inc. (ALT)Contact Levi & Korsinsky Before October 6, 2025 - Newsfile
Altimmune Appoints New Chief Medical Officer - TipRanks
ALTIMMUNE CLASS ACTION REMINDER: Bragar Eagel & Squire, - GlobeNewswire
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims o - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming DeadlinesALT - WV News
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune - MarketScreener
ALT Deadline: ALT Investors with Losses in Excess of $50K Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit - Morningstar
Shareholders that lost money on Altimmune, Inc.(ALT) Urged - GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune - Newsfile
Altimmune, Inc. (NASDAQ: ALT) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit - Prime Publishers, Inc.
Securities Lawsuit Alert: Altimmune, Inc. (ALT) InvestorsContact Levi & Korsinsky Before October 6, 2025 - ACCESS Newswire
Portnoy Law Firm Announces Class Action on Behalf of Altimmune, Inc. Investors - GlobeNewswire
Shareholders SueWallSt in New Class Action Against Altimmune, Inc.Act Now - Nasdaq
Relative strength of Altimmune Inc. in sector analysisPortfolio Risk Summary & Long-Term Safe Investment Plans - newser.com
ALT DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages - GlobeNewswire
Altimmune at Stifel Forum: Strategic Insights on MASH Drug - Investing.com
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune - GlobeNewswire
Altimmune, Inc. Sued for Securities Law Violations - Benzinga
About Us - FinancialContent
Does Altimmune Inc. qualify in momentum factor screeningStop Loss & Accurate Entry/Exit Alerts - newser.com
Altimmune appoints new chief medical officer to lead pemvidutide program By Investing.com - Investing.com Nigeria
The Gross Law Firm Reminds Altimmune Investors of the - GlobeNewswire
Class Action Lawsuit Filed Against Altimmune, Inc. (ALT)Recover LossesContact Levi & Korsinsky Before October 6, 2025 - ACCESS Newswire
ALTIMMUNE (ALT) DEADLINE ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securitie - GuruFocus
Using economic indicators to assess Altimmune Inc. potentialPrice Action & Precise Trade Entry Recommendations - newser.com
Altimmune Appoints Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer - citybiz
Can Altimmune Inc. rally from current levels2025 Price Targets & High Return Stock Watch Alerts - newser.com
Shareholders that lost money on Altimmune, Inc.(ALT) should contact The Gross Law Firm about pending Class ActionALT - PR Newswire
Altimmune appoints new chief medical officer to lead pemvidutide program - Investing.com
Finanzdaten der Altimmune Inc-Aktie (ALT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Altimmune Inc-Aktie (ALT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| WEAVER GREGORY L | Chief Financial Officer |
Mar 13 '25 |
Buy |
5.20 |
10,000 |
51,996 |
10,000 |
| Garg Vipin K | President and CEO |
Feb 02 '25 |
Option Exercise |
0.00 |
18,950 |
0 |
363,364 |
| Garg Vipin K | President and CEO |
Feb 01 '25 |
Option Exercise |
0.00 |
16,545 |
0 |
351,645 |
| Garg Vipin K | President and CEO |
Jan 30 '25 |
Option Exercise |
0.00 |
26,775 |
0 |
342,696 |
| Harris Matthew Scott | Chief Medical Officer |
Feb 02 '25 |
Option Exercise |
0.00 |
7,775 |
0 |
84,564 |
| Harris Matthew Scott | Chief Medical Officer |
Feb 01 '25 |
Option Exercise |
0.00 |
6,166 |
0 |
78,898 |
| Harris Matthew Scott | Chief Medical Officer |
Jan 30 '25 |
Option Exercise |
0.00 |
9,275 |
0 |
74,000 |
| Roberts M Scot | Chief Scientific Officer |
Feb 02 '25 |
Option Exercise |
0.00 |
7,775 |
0 |
75,536 |
| Roberts M Scot | Chief Scientific Officer |
Feb 01 '25 |
Option Exercise |
0.00 |
6,166 |
0 |
69,562 |
| Roberts M Scot | Chief Scientific Officer |
Jan 30 '25 |
Option Exercise |
0.00 |
9,275 |
0 |
62,921 |
5.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):